ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025
Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionThis study aimed to determine the role of postoperative adjuvant therapy in patients with thymic carcinoma following complete resection.
methodsWe conducted a retrospective analysis of patients with stage I-III or N1+ thymic carcinomas who underwent complete resection at our center between 2006 and 2020. Data on the clinical characteristics and postoperative adjuvant therapies were collected.
resultsOne hundred and twenty patients were enrolled. Five (4.2%) patients received only postoperative chemotherapy, 36 (33.0%) received only postoperative radiotherapy, 75 (62.5%) received postoperative chemoradiotherapy, and four (3.3%) did not receive any postoperative therapy. During a median follow-up period of 65 months, disease failure was observed in 46 (38.3%) patients, and 28 (23.3%) patients died. The 5‑year disease-free survival (DFS) and overall survival (OS) rates were 58.7 and 81.4%, respectively. Patients who underwent different postoperative therapies exhibited varying prognoses. Radiotherapy reduced the risks of failure (p < 0.001) and death (p < 0.001), whereas chemotherapy did not (p = 0.198 and 0.260 respectively). Subgroup analyses revealed that stage III/IV patients who received chemotherapy had a lower relapse risk (p = 0.045) and improved OS (p = 0.064). Multivariate analysis demonstrated that radiotherapy alone (hazard ratio [HR], 0.24; p = 0.023) independently predicted OS.
conclusionsAdjuvant radiotherapy should be recommended for patients with thymic carcinoma who have undergone complete resection. Further exploration is needed to clarify the role of adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.